Syndax Pharmaceuticals Shares Rise 8% After Positive Data for Revumenib Leukemia Treatment

By Chris Wack Syndax Pharmaceuticals shares were up 8% to $18 after the company said it saw positive data from trials of revumenib in combination with...

Related Keywords

Chris Wack ,Syndax Pharmaceuticals ,Article Normal ,Pharmaceuticals ,Cancer Drugs ,Healthcare Life Sciences ,Specialized Drugs Medications ,Financial Performance ,Share Price Movement Disruptions ,Corporate Industrial News ,Cancer ,Political General News ,Health ,Blood Cancer ,Medical Conditions ,Equity Markets ,Commodity Financial Market News ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,Synd ,Sndx ,Share Price Movement ,Disruptions ,Corporate ,Industrial News ,Political ,General News ,Commodity ,Financial Market News ,Healthcare ,Life Sciences ,Specialized Drugs ,Medications ,